Short Interest in Capstone Therapeutics Corp. (NASDAQ:CAPS) Grows By 52.5%

Capstone Therapeutics Corp. (NASDAQ:CAPS) was the target of a large increase in short interest in March. As of March 13th, there was short interest totaling 157,346 shares, an increase of 52.5% from the February 26th total of 103,151 shares. Based on an average trading volume of 507,332 shares, the short-interest ratio is presently 0.3 days. Approximately 4.2% of the shares of the company are short sold.

Capstone Therapeutics Price Performance

NASDAQ CAPS opened at $0.63 on Monday. The company has a 50-day moving average price of $0.64 and a two-hundred day moving average price of $0.86. Capstone Therapeutics has a 52 week low of $0.49 and a 52 week high of $3.29. The stock has a market cap of $5.75 million, a price-to-earnings ratio of -0.67 and a beta of -1.23. The company has a current ratio of 0.95, a quick ratio of 0.35 and a debt-to-equity ratio of 0.29.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Capstone Therapeutics in a report on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has a consensus rating of “Sell”.

Institutional Trading of Capstone Therapeutics

An institutional investor recently bought a new position in Capstone Therapeutics stock. World Investment Advisors bought a new stake in shares of Capstone Therapeutics Corp. (NASDAQ:CAPS) during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 29,000 shares of the company’s stock, valued at approximately $38,000. World Investment Advisors owned approximately 0.40% of Capstone Therapeutics at the end of the most recent reporting period. Hedge funds and other institutional investors own 2.55% of the company’s stock.

Capstone Therapeutics Company Profile

Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.